196 related articles for article (PubMed ID: 22220206)
1. Enhanced discrimination of malignant from benign pancreatic disease by measuring the CA 19-9 antigen on specific protein carriers.
Yue T; Maupin KA; Fallon B; Li L; Partyka K; Anderson MA; Brenner DE; Kaul K; Zeh H; Moser AJ; Simeone DM; Feng Z; Brand RE; Haab BB
PLoS One; 2011; 6(12):e29180. PubMed ID: 22220206
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of serum MUC5AC in combination with CA19-9 for the diagnosis of pancreatic cancer.
Zhang J; Wang Y; Zhao T; Li Y; Tian L; Zhao J; Zhang J
World J Surg Oncol; 2020 Feb; 18(1):31. PubMed ID: 32028958
[TBL] [Abstract][Full Text] [Related]
3. Validation of four candidate pancreatic cancer serological biomarkers that improve the performance of CA19.9.
Makawita S; Dimitromanolakis A; Soosaipillai A; Soleas I; Chan A; Gallinger S; Haun RS; Blasutig IM; Diamandis EP
BMC Cancer; 2013 Sep; 13():404. PubMed ID: 24007603
[TBL] [Abstract][Full Text] [Related]
4. Identification of blood-protein carriers of the CA 19-9 antigen and characterization of prevalence in pancreatic diseases.
Yue T; Partyka K; Maupin KA; Hurley M; Andrews P; Kaul K; Moser AJ; Zeh H; Brand RE; Haab BB
Proteomics; 2011 Sep; 11(18):3665-74. PubMed ID: 21751362
[TBL] [Abstract][Full Text] [Related]
5. CA-125, but not galectin-3, complements CA 19-9 for discriminating ductal adenocarcinoma versus non-malignant pancreatic diseases.
Coppin L; Benomar K; Corfiotti F; Cattan S; Renaud F; Lapere C; Leteurtre E; Vantyghem MC; Truant S; Pigny P
Pancreatology; 2016; 16(1):115-20. PubMed ID: 26613889
[TBL] [Abstract][Full Text] [Related]
6. CEA, CA 19-9, and CA 125 in the differential diagnosis of benign and malignant pancreatic diseases with or without jaundice.
Duraker N; Hot S; Polat Y; Höbek A; Gençler N; Urhan N
J Surg Oncol; 2007 Feb; 95(2):142-7. PubMed ID: 17262731
[TBL] [Abstract][Full Text] [Related]
7. Improved Pancreatic Adenocarcinoma Diagnosis in Jaundiced and Non-Jaundiced Pancreatic Adenocarcinoma Patients through the Combination of Routine Clinical Markers Associated to Pancreatic Adenocarcinoma Pathophysiology.
Ferri MJ; Saez M; Figueras J; Fort E; Sabat M; López-Ben S; de Llorens R; Aleixandre RN; Peracaula R
PLoS One; 2016; 11(1):e0147214. PubMed ID: 26808421
[TBL] [Abstract][Full Text] [Related]
8. Diverse monoclonal antibodies against the CA 19-9 antigen show variation in binding specificity with consequences for clinical interpretation.
Partyka K; Maupin KA; Brand RE; Haab BB
Proteomics; 2012 Jul; 12(13):2212-20. PubMed ID: 22623153
[TBL] [Abstract][Full Text] [Related]
9. Improved diagnosis of pancreatic adenocarcinoma using haptoglobin and serum amyloid A in a panel screen.
Firpo MA; Gay DZ; Granger SR; Scaife CL; DiSario JA; Boucher KM; Mulvihill SJ
World J Surg; 2009 Apr; 33(4):716-22. PubMed ID: 19082654
[TBL] [Abstract][Full Text] [Related]
10. Multianalyte profiling of serum cytokines for detection of pancreatic cancer.
Zeh HJ; Winikoff S; Landsittel DP; Gorelik E; Marrangoni AM; Velikokhatnaya L; Winans MT; Lee K; Moser A; Bartlett D; Lotze MT; Siegfried JM; Whitcomb D; Papacristou G; Slivka A; Bigbee WL; Lokshin AE
Cancer Biomark; 2005; 1(6):259-69. PubMed ID: 17192050
[TBL] [Abstract][Full Text] [Related]
11. Definitive Characterization of CA 19-9 in Resectable Pancreatic Cancer Using a Reference Set of Serum and Plasma Specimens.
Haab BB; Huang Y; Balasenthil S; Partyka K; Tang H; Anderson M; Allen P; Sasson A; Zeh H; Kaul K; Kletter D; Ge S; Bern M; Kwon R; Blasutig I; Srivastava S; Frazier ML; Sen S; Hollingsworth MA; Rinaudo JA; Killary AM; Brand RE
PLoS One; 2015; 10(10):e0139049. PubMed ID: 26431551
[TBL] [Abstract][Full Text] [Related]
12. A Combination of MUC5AC and CA19-9 Improves the Diagnosis of Pancreatic Cancer: A Multicenter Study.
Kaur S; Smith LM; Patel A; Menning M; Watley DC; Malik SS; Krishn SR; Mallya K; Aithal A; Sasson AR; Johansson SL; Jain M; Singh S; Guha S; Are C; Raimondo M; Hollingsworth MA; Brand RE; Batra SK
Am J Gastroenterol; 2017 Jan; 112(1):172-183. PubMed ID: 27845339
[TBL] [Abstract][Full Text] [Related]
13. Serum carbohydrate antigen 19-9 in pancreatic adenocarcinoma: a mini review for surgeons.
Goh SK; Gold G; Christophi C; Muralidharan V
ANZ J Surg; 2017 Dec; 87(12):987-992. PubMed ID: 28803454
[TBL] [Abstract][Full Text] [Related]
14. Applicative Value of Serum CA19-9, CEA, CA125 and CA242 in Diagnosis and Prognosis for Patients with Pancreatic Cancer Treated by Concurrent Chemoradiotherapy.
Gu YL; Lan C; Pei H; Yang SN; Liu YF; Xiao LL
Asian Pac J Cancer Prev; 2015; 16(15):6569-73. PubMed ID: 26434876
[TBL] [Abstract][Full Text] [Related]
15. Growth differentiation factor (GDF-15) concentration combined with Ca125 levels in serum is superior to commonly used cancer biomarkers in differentiation of pancreatic mass.
Hogendorf P; Durczyński A; Skulimowski A; Kumor A; Poznańska G; Strzelczyk J
Cancer Biomark; 2018 Feb; 21(3):505-511. PubMed ID: 29171983
[TBL] [Abstract][Full Text] [Related]
16. Identification of Serum Biomarker Panels for the Early Detection of Pancreatic Cancer.
Song J; Sokoll LJ; Pasay JJ; Rubin AL; Li H; Bach DM; Chan DW; Zhang Z
Cancer Epidemiol Biomarkers Prev; 2019 Jan; 28(1):174-182. PubMed ID: 30333219
[TBL] [Abstract][Full Text] [Related]
17. Periostin and CA242 as potential diagnostic serum biomarkers complementing CA19.9 in detecting pancreatic cancer.
Dong D; Jia L; Zhang L; Ma N; Zhang A; Zhou Y; Ren L
Cancer Sci; 2018 Sep; 109(9):2841-2851. PubMed ID: 29945294
[TBL] [Abstract][Full Text] [Related]
18. The clinical utility of CA125/MUC16 in pancreatic cancer: A consensus of diagnostic, prognostic and predictive updates by the Chinese Study Group for Pancreatic Cancer (CSPAC).
Liu L; Xiang J; Chen R; Fu D; Hong D; Hao J; Li Y; Li J; Li S; Mou Y; Mai G; Ni Q; Peng L; Qin R; Qian H; Shao C; Sun B; Sun Y; Tao M; Tian B; Wang H; Wang J; Wang L; Wang W; Wang W; Zhang J; Zhao G; Zhou J; Yu X;
Int J Oncol; 2016 Mar; 48(3):900-7. PubMed ID: 26718269
[TBL] [Abstract][Full Text] [Related]
19. Cancer antigens 19-9 and 125 in the differential diagnosis of pancreatic mass lesions.
Cwik G; Wallner G; Skoczylas T; Ciechanski A; Zinkiewicz K
Arch Surg; 2006 Oct; 141(10):968-73; discussion 974. PubMed ID: 17043274
[TBL] [Abstract][Full Text] [Related]
20. Detection of serum tumor markers in the diagnosis and treatment of patients with pancreatic cancer.
Jiang XT; Tao HQ; Zou SC
Hepatobiliary Pancreat Dis Int; 2004 Aug; 3(3):464-8. PubMed ID: 15313690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
